Author(s):
Kashish R. Mulani, B.P. Chaudhari, V. K. Redasani, Kalyani Gardi
Email(s):
kashishmulani22@gmail.com
DOI:
10.52711/2231-5659.2025.00029 
Address:
Kashish R. Mulani*, B.P. Chaudhari, V. K. Redasani, Kalyani Gardi
YSPM’s Yashoda Technical Campus, Faculty of Pharmacy, Wadhe, Satara.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Drug discovery is a process which aims at identifying a compound therapeutically useful in curing and treating disease. This process involves the identification of candidates, synthesis, characterization, validation, optimization, screening and assays for therapeutic efficacy. A compound will start the drug development process before clinical trials if it proved its value in these studies. To produce a medication that is safe, effective, and satisfies all regulatory requirements, the new drug development process must go through multiple stages. Our article’s primary focus is that the process is complex, lengthy, and costly enough that every new drug finally approved for clinical use must take into account a large number of biological targets, and new research instruments may be required to examine each new target. It’s a difficult and drawn-out process from initial discovery to a medicine that can be sold. From the time of discovery to the approved drugs, it takes 12 to 15 years and costs roughly $1 billion USD. On an average, a million molecules screened but only a single is explored in late stage clinical trials and is finally made obtainable for patients. This article provides a brief outline of the processes of new drug discovery and development.
Cite this article:
Kashish R. Mulani, B.P. Chaudhari, V. K. Redasani, Kalyani Gardi. Drug Discovery and Development. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(2):185-0. doi: 10.52711/2231-5659.2025.00029
Cite(Electronic):
Kashish R. Mulani, B.P. Chaudhari, V. K. Redasani, Kalyani Gardi. Drug Discovery and Development. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(2):185-0. doi: 10.52711/2231-5659.2025.00029 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-2-14
REFERENCES:
1. SIS/draw, and chemsketch. J. Chem. Inf. Comput. Sci. 2004; 44: 1886–1890 ().
2. Vrushali G. Raut, et al. Influence of newly Synthesized Superdisintegrant on Dissolution Rate Enhancement of Carbomazepine using Liquid. solid Compact Technique. Asian Journal of Research in Pharmaceutical Sciences. 2022.
3. Kiriiri, G. K., Njogu, P. M. and Mwangi, A. N. Exploring different Approaches to improve the success of drug discovery and development Projects: a review. 2020; 9.
4. Deore, A. B., Dhumane, J. R., Wagh, R. and Sonawane, R. The Stages of Drug Discovery and Development Process. Asian J. Pharm. Res. Dev. 2019; 7: 62–67.
5. Svennebring, A. M. and Wikberg, J. E. S. Net present value approaches for drug discovery. Springerplus. 2013; 2:1–7.
6. Nicolaou, K. C. Advancing the Drug Discovery and Development Process. Angew.Chemie. 2014; 126; 9280–9292.
7. Mohs, R. C. and Greig, N. H. Drug discovery and development: Role of Basic biological research. Alzheimer’s Dement. Transl. Res. Clin. Interv. 2017; 3: 651–657.
8. Zhong, X. and Moseley, G. B. Mission possible: Managing innovation In drug discovery. Nat. Biotechnol. 2007; 25: 945–946.
9. Berdigaliyev, N. and Aljofan, M. An overview of drug discovery and Development.Future Med. Chem. 2020; 12: 939–947.
10. Jackson, M., Marks, L., May, G. H. W. and Wilson, J. B. The genetic Basis of disease. Essays Biochem. 2018; 62: 643–723.
11. Ban, T. A. The role of serendipity in drug discovery. Dialogues Clin. Neurosci. 2006; 8: 335–344.
12. Weiser, J., Weiser, A. A., Shenkin, P. S. and Still, W. C. Neighbor-list Reduction: Optimization for computation of molecular van der Waal and solvent-accessible surface areas. J. Comput. Chem. 19, 797–808 (1998).
13. Holford, N., Ma, S. C. and Ploeger, B. A. Clinical trial simulation: A Review. Clin. Pharmacol. Ther. 88, 166–182 (2010).
14. McKee, A. E., Farrell, A. T., Pazdur, R. and Woodcock, J. The Role of The U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology. Oncologist 15, 13–18 (2010).
15. Clayden, J., Moran, W. J., Edwards, P. J. and Laplante, S. R. The Challenge of atropisomerism in drug discovery. Angew. Chemie – Int. Ed. 48, 6398–6401 (2009).
16. Zisowsky, J., Krause, A. and Dingemanse, J. Drug development for Pediatric populations: Regulatory aspects. Pharmaceutics 2, 364–388 (2010).
17. Balganesh, T., Kundu, T. K., Chakraborty, T. K. and Roy, S. Drug Discovery Research in India: Current State and Future Prospects. 724–726 (2014).
18. Russu WA. The Climate is Right to Accelerate New Drug Development for Neglected Diseases. Outlook Emerg Drugs. 2012; 1: 1.
19. Frohlich E. Alternatives to Animal Procedures in Drug Development. J Mol PharmOrg Process Res. 2016; 4: 132.
20. Cacabelos R. The Complexity of Alzheimer’s disease Pharmacogenomics and Metabolomics in Drug Development.Metabolomics. 2016; 6: e145.
21. Shastri PN. FDA Expedited Drug Development Programs. J Pharmacovigil. 2016; 4: e156.
22. Subudhi BB, et al. Updates in Drug Development Strategies against Peptic ulcer. JGastrointest Dig Syst. 2016; 6: 398.
23. Shimizu T and Nakagawa K. Novel Drug Development of the Next- Generation T790M Mutant Specific Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer. Biochem Anal Biochem. 2016; 5: 258.
24. Zhao Y. Towards Structural Based Drug Development for Ebola Virus Disease. J Chem Biol Ther. 2016; 1: e101.
25. Geert ER, et al. Selection Strategy of In Vivo Models for Ophthalmic Drug Development in Diabetic Retinopathy. J Mol Genet Med. 2016; 10: 202.
26. Nayeem N, et al. Gallic Acid: A Promising Lead Molecule for Drug Development. J App Pharm. 2016;8:213.
27. Emmanuel A, et al. Preliminary Identification of Lactate Dehydrogenase Inhibitors towards Anticancer Drug Development. J Develop Drugs. 2015; 4: 132.
28. Elhassa GO and Alfarouk KO. Stem Cell Therapy in Drug Discovery and Development. J Pharmacovigilance. 2015; 3: e140.
29. Melchior ACB, et al. Bromodomain as New Targets in Drug Discovery. BiochemPharmacol (Los Angel) 2015; 4: e176.
30. Goldberg JM and Panoff J. Pediatric Oncology Drug Development: A Case Reportand Pathways Forward. Pediat Therapeut. 2014; 4: 202.
31. Lu DY et al. Anticancer Drug Development, a Matter of Money or a Matter of Idea? Metabolomics. 2015; 5: e134.
32. Prado CM, et al. New Pharmacological Targets for Asthma Drug Development. J Allergy Ther. 2014; 5: 170.
33. Bourgailh J, et al. ViewLux™ Microplate Imager for Metabolite Profiling: Validation and Applications in Drug Development. J Anal Bioanal Tech. 2014; 5: 185.
34. Lu DY and Che JY. Rethink Of Diabetes Treatment and Drug Development. Cell Dev Biol. 2014; 3 :e125.
35. Papanastasopoulos P. Functional Imaging in Cancer Drug Development: A Mini- Review. J Med Diagn Meth; 2014; 3: 157.
36. Lee MKK and Dilq. Drug Development in Cell Culture: Crosstalk from the Industrial Prospects. J Bioequiv Availab. 2014; 6: 096-114.
37. Shengqian Wu, et al. Role of In-silico modeling in Drug Development for Inhalation Treatment. J Mol Pharm Org Process Res. 2013; 1: 106.
38. Jackson R. What can systems pharmacology contribute to drug development? Disease modelling as a predictive tool. BioDiscovery 2012; 4: 4.
39. Ceron-Carrasco JP, et al. Application of Computational Drug Discovery Techniques for Designing New Drugs Against Zika Virus. Drug Des. 2016; 5: e131
40. Ganesan A and Barakat K. Target fishing: a key to unlock the One-To- Many puzzle in drug discovery. J Pharma Care Health Sys. 2016; 3: e141.
41. Valayil JM. Activation of Microbial Silent Gene Clusters: Genomics Driven Drug Discovery Approaches. Biochem Anal Biochem. 2016; 5: 276.
42. Bueno J. Antimicrobial Adjuvants Drug Discovery, the Challenge of Avoid the Resistance and Recover the Susceptibility of Multidrug- Resistant Strains. J Microb Biochem Technol. 2016; 8: 169-176.
43. Melchior ACB, et al. Bromodomain as New Targets in Drug Discovery. Biochem Pharmacol (Los Angel). 2015;4:e176.
44. Ashwini R. Ghorpade, et al., “Review on vesicular Drug Delivery system: Aquaomes”, “Asian Journal of Research in Chemistry” 2024 March-April ,0974-4150
45. Agrawal P. Stem Cell Therapy in Drug Discovery and Development. J Pharmacovigilance. 2015; 3: e140.
46. Zambon S, et al. Development of a Rapid and Cost Effective Assay for the Screening of Reversible Cytochrome P450 Inhibition in Parallel with Cyp3a4 Metabolism-Dependent Inhibition Using Recombinant Proteins. Pharm Anal Acta. 2015; 6: 389.
47. Vrushali G Raut, et al, “A Review Mechanism of Role of superdisintogrants in the Development of Mouth Dissolving Tablets”, “International Journal; Pharma Tech Research” 2011, 2455-9563.
48. Xiong J. Multiple Targeting Routes of MicroRNA-22 Inform Cancer Drug Discovery. Gene Technol. 2015; 4: e114.
49. Sanaki T, et al. Improvements in the High-Performance Liquid Chromatography and Extraction Conditions for the Analysis of Oxidized Fatty Acids Using a Mixed-Mode Spin Column. Mod Chem appl. 2015; 3: 161.
50. Baig MH, et al. Drug Discovery and In Silico Techniques: A Mini- Review. Enz Eng. 2015; 4: 123.
51. Tyagi AK and Prasad S. Drug Discovery Inspired by Mother Nature for Cancer Therapy. Biochem Physiol. 2015;4:e128.
52. Dembitsky VM. Astonishing Diversity of Natural Peroxides as Potential Therapeutic Agents. J Mol Genet Med. 2015; 9: 163.
53. Den Haan HD, et al. Application of Modern Drug Discovery Techniques in the Context of Diabetes Mellitus and Atherosclerosis. Drug Des. 2015;4:e125.
54. Marjeta U. Chemo Proteomics, a Valuable Tool for Biomarker and Drug Discovery. Mol Biol. 20143:e117.
55. Nazem A. Alzheimer’s Disease Drug Discovery is Misled by Wrong Animal Models. J Gerontol Geriat Res. 2014;3:e127.
56. Bueno J. Biosensors in Antimicrobial Drug Discovery: Since Biology until Screening Platforms. J Microb Biochem Technol. 2014; S10: 002.
57. R.R Shinde, et al, “Pharmacosome as a vesicular Drug Delivery system”, “Asian Journal of Research in Pharmaceutical Science”, 2022 Oct-Dec, 2231-5659.
58. Helieh S. Oz. Toxoplasmosis, Pancreatitis, Obesity and Drug Discovery. Pancreat Disord Ther. 2014; 4: 138.
59. Agrawal P. Drug Discovery and Development: An Insight into Pharmacovigilance. J Pharmacovigilance. 2014;2:e120.
60. Li Y and Yang ST. Advances in Human Pluripotent Stem Cells for Regenerative Medicine and Drug Discovery. J Tissue Sci Eng. 2014; 5: e127.
61. Chang HW. Drug Discovery and Bioinformatics of Marine Natural Products. J Marine Sci Res Dev. 2013;4:e121.
62. Shivani Deshmukh, et al, “A Review on Diverging approaches to Fabricate Polymeric Nanoparticles”, “Asian Journal of Research in Pharmaceutical Science”, 2023 Oct-Dec, 2231-5659
63. Sanket Nikam, et al, “Pulsatile Delivery of Drug for a Range of Diseases”, “Asian Journal of Research in pharmaceutical Sciences”, 2022 Oct-Dec. 2231-5659.
64. Mishra NK and Shukla M. Application of Computational Proteomics and Lipidomics in Drug Discovery. J Theory Comput Sci. 2014; 1: 105.
65. Feng Y and Wang N. The New Generation of Drug Discovery and its Analytical Technologies. J Bioequiv Availab. 2013;5:e42.
66. Ravindran S, et al. Significance of Biotransformation in Drug Discovery and Development. J Biotechnol Biomaterial. 2012; S13: 005.
67. Gupta D. Pharmacogenomics in Drug Discovery and Development. J Develop Drugs. 2013; 2: e126.
68. Pradeep KV, et al. Importance of ADME and Bioanalysis in the Drug Discovery. J Bioequiv Availab. 2013; 5: e31.
69. Barile FA. Pri. Nciples of Toxicological Testing. CRC Press, USA, 2008.
70. Bhagyashri V. Aiwale, et al, “A Review on in situ Gel of Gastro Retentive Drug Delivery System”, “Asian Journal of Research in Pharmaceutical Sciences”, 2022 Oct- Dec ,2231-5659.
71. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials. 4th ed. New York: Springer Science and Business Media LLC; 2010.
72. Faqi AS. A comprehensive guide to toxicology in preclinical drug development. Waltham, MA: Elsevier; 2013.
73. Kaustubh Jagtap, et al, “Quality by Design (gbd) concept Review in Pharmaceutical”, “Asian Journal of Research in Chemistry” 2022 July-Aug, 0974-4150.
74. Bharatee Chaudhari, Kartika Daniel, “A Validated RP-HPLC Method for simultaneous Estimation of Tizanidine and Nimesulide in Bulk and Pharmaceutical and Technology”, 2020 Sep, 0974-360x.
75. Vogel HG. Drug Discovery and Evaluation 2nd edition. Springer, USA, 2002.
76. Karara AH, Edeki T, McLeod J, et al. PhRMA survey on the conduct Of first-in- human clinical trials under exploratory investigational new Drug applications. Journal of Clinical Pharmacology, 2010; 50:380- 391.
77. Fitzpatrick S. The clinical trial protocol. Buckinghamshire: Institute of Clinical Research; 2005.
78. Friedhoff L. New Drugs: An Insider‘s Guide to the FDA‘s New Drug Approval Process for Scientists, Investors and Patients. New York, NY: PSPG Publishing; 2009.
79. FDA (2003). New Drug Approval Reports. http://www.fda.gov/cder/rdmt/default.htm.
80. FDA, The FDA and the Drug Development Process: How the FDA Insures that drugs are safe and effective, FDA Fact sheet, 2002.
81. Adams CP, and Brantner VV. New Drug Development: Estimating Entry from human clinical trials. Bureau of Economics Federal Trade Commission. 2003.
82. Neha B. Waghmode, et al, “Review on Colon Targeted Drug Delivery System”, “Asian Journal of Research in Chemistry”, 2024 May-June ,0974-4150.
83. Sisodiya, D., Pandey, P. and Dashora, K. Drug Designing Softwares and Their Applications in New Drug Discover. J. Pharm. Res. 5, 124– 126 (2012).
84. Li, Z., Wan, H., Shi, Y. and Ouyang, P. Personal experience with four Kinds of chemical structure drawing software: Review on chemdraw, Chemwindow, I
85. Hopkinson, G. A. The Accord Component Software Approach. J. Chem. Inf. Comput. Sci. 37, 143–145 (1997).
86. Akram, W. and Garud, N. Design expert as a statistical tool for Optimization of 5- ASA-loaded biopolymer-based nanoparticles using Box Behnken factorial design. Futur. J. Pharm. Sci. 7, (2021).
87. Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701–1718 (2005).
88. Nurisso, A., Bravo, J., Carrupt, P. A. and Daina, A. Molecular docking Using the molecular lipophilicity potential as hydrophobic descriptor: Impact on GOLD docking performance. J. Chem. Inf. Model. 52, 1319–1327 (2012).
89. Yuan, S., Chan, H. C. S. and Hu, Z. Using PyMOL as a platform for Computational drug design. Wiley Interdiscip. Rev. Comput. Mol. Sci.7, 1–10 (2017).
90. Gurdeep Singh, R. et al. Unipept 4.0: Functional Analysis of Metaproteome Data.J. Proteome Res. 18, 606–615 (2019)